Top Markets
#1 ORDI ORDI +105.28%
#2 pippin pippin +48.89%
#3 tomiNet tomiNet +42.76%
#4 SATS (Ordinals) SATS (Ordinals) +41.44%
#5 1000SATS (Ordinals) 1000SATS (Ordinals) +40.63%
#6 Axelar Axelar +28.30%
#7 Bio Protocol Bio Protocol +27.90%
#8 Swarms Swarms +26.30%
#9 Drift Protocol Drift Protocol +25.62%
#10 MemeCore MemeCore +24.82%
Coin of the day
ORDI ORDI
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Classifica tra le azioni #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Prezzo delle azioni
$0.00047446
Capitalizzazione di mercato
$82.80
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-98.16%
Paese
FR
Scambia Neovacs S.A. (ALNEV)

Categoria

Healthcare
Ricavi di Neovacs S.A. (ALNEV)
Ricavi nel Dec 2024 TTM: $303.12K
Secondo gli ultimi rapporti finanziari di Neovacs S.A., i ricavi attuali dell'azienda (TTM) sono pari a $303.12K. Nel 2023, l'azienda ha registrato ricavi di $589.67K un aumento rispetto a i ricavi dell'anno 2022, che erano pari a $1.19K. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Neovacs S.A. da 2007 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $303.12K -20.48%
2024 $381.21K -35.35%
2023 $589.67K 49,335.08%
2022 $1.19K -95.36%
2021 $25.69K -29.17%
2020 $36.27K 0.00%
2019 0.00 -100.00%
2018 $166.63K 0.00%
2017 0.00 -100.00%
2016 $16.23K -89.89%
2015 $160.58K -6.42%
2014 $171.60K 317.73%
2013 $41.08K 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 -100.00%
2008 $75.78K -59.14%
2007 $185.43K 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 16,015,729.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 3,971,340.03%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 4,731,589.19%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 2,996,119.45%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 1,811,461.99%
NL